AbbVie is expected to achieve strong long-term growth driven by its drugs Skyrizi and Rinvoq, which are forecasted to deliver double-digit revenue growth by 2026. The company is recovering from Humira's sales decline and is likely to increase dividends and pursue more business acquisitions. However, its obesity drug pipeline needs expansion and differentiation, making timely acquisitions critical to stay competitive. Despite a recent 10% share price drop, AbbVie's fundamentals remain solid for future growth.
SkinMedica, part of Allergan Aesthetics under AbbVie, has launched a Regenerative Science Advisory Board composed of leading skin health experts to guide future innovation. The company also expanded its R&D facility in Irvine, California, integrating...
Big pharmaceutical companies are confronting a $300 billion loss in drug patents by 2030, prompting a surge in acquisitions of mid-size biotech firms with promising drug pipelines. In 2026, biopharma deal values are expected to exceed $250 billion, t...
